The Pharmaceutical Market: Finland

Publisher Name :
Date: 25-Apr-2013
No. of pages:

OVERVIEW OF THE PHARMACEUTICAL MARKET IN FINLAND

The macroenvironment for the Finnish pharmaceutical industry is improving. Politically, the new six-party coalition is larger and represents a broader spectrum of opinion than is usual, which could make it unstable. However, the Economist Intelligence Unit (EIU) believes that it will last out its four-year term. Economically, recovery from the downturn is stalling due to the euro area debt crisis. Legally, Finland remains on the USTR’s Watch List in 2011 due to concerns over patent protection. Demographically, Finland has one of the largest proportions of population over the age of 65 in Western Europe. Latest projections expect that the population aged 65 and over will constitute more than one-fifth of the total population by 2017. The ageing population means that healthcare is increasingly focused on preventative care.

The Finnish government has introduced several cost-containment measures in recent years in an effort to curb rising healthcare costs. One of the latest affecting the pharmaceutical market in Finland is a reference pricing system. It is hoped that the new system will reduce the use of expensive pharmaceutical products, thus lowering the costs for patients and reducing the pressure to raise health insurance payments. Generic substitution in Finland has been extended to include products with an analogy process patent. As a result, generic substitution will be more effective in terms of saving money, but Finnish manufacturers of patented original products now enter generic price competition several years before product patents expire in other European countries.

There are three leading domestic producers in Finland; Orion, Verman and Vitabalans. Multinational companies Bayer and Santen also have production facilities in Finland. The top ten pharmaceutical companies in Finland had combined sales of over 1.0 billion euros at wholesale prices in 2010, equal to a share of over half of the market. The leading company was Orion, with a market share of nearly 10.0%. This was followed by Pfizer, Novartis, AstraZeneca and GlaxoSmithKline. In the biologic sector, Biotie Therapies completed its acquisition of Synosia Therapeutics in February 2011, while Ark Therapeutics entered into a formal agreement to divest the majority of its woundcare business in the same month.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

The Pharmaceutical Market: Finland

Table Of Contents
N/A

  • Global Dental Implants Market Driven by Demand in Cosmetic Dentistry
    The global market for dental implants has been witnessing steady growth in the last couple of years due to increased demand for cosmetic dentistry and rise in incidences of dental disorders. People’s awareness about aesthetic dentistry procedures has increased in recent years, which is also fueling the growth of the dental implant market. With economic [...]
  • Air Traffic Management and Control Market Driven by Technological Advancement
    The global market for air traffic management and control has grown steadily in the last couple of years with increase in air traffic volume and congestion. Air Traffic Control (ATC) consists of an elaborate system of ground stations, radar arrays and professional air traffic controllers. With increase in air travel for business and leisure, as [...]
  • Global Stem Cell Therapy Industry Witnesses Steady Growth
    Stem cell research which is one of the most contemporary areas of biology has developed rapidly in the last couple of years. Increased funding in stem cell research by both government and private organizations is one of the main drivers in the stem cell therapy industry. Stem cells are used in various medical therapies such [...]
  • Global Lubricant Market Driven by Increased Demand in Automotive Industry
    With growth in the automobile industry, the demand for lubricants has also increased. The robust growth in manufacturing with increase in industrial production, particularly in countries such as China and India are also fueling the demand for lubricants. In 2013, the global market for lubricants had reached a value of 123.64 billion USD. By 2020, [...]
  • Global Cybersecurity Market Driven by Increase in Cyber Attacks
    In recent years, the global market for cybersecurity has grown steadily, with the rapid adoption of cloud-based services. As more and more corporate and government organizations are realizing the importance of protecting data and intellectual property, the market for cybersecurity is going to expand. In 2014, the global market for cybersecurity was valued at 95.60 [...]
  • Graft-Versus-Host Disease (GVHD) Treatment Market worth $407 million by 2018
  • The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm GlobalData. The company’s latest report* states …

  • Poland Pharmaceutical Industry Growing at 8.3% CAGR to 2020
  • Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in mark-up prices and the country’s stringent drug …

  • Asia-Pacific, Led by China, Drive the Global Methanol Industry
  • China is driving the global methanol industry, with tremendous demand from both its energy and petrochemicals sectors. It accounts for 87.9% of Asia-Pacific’s (APAC) methanol capacity, and 51.9% of the global methanol capacity. Despite a large planned capacity increase in …

  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • Puerto Rico Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 99
    BMI View: The pharmaceutical manufacturing industry will continue to be an economic mainstay for Puerto Rico. However, the country is gradually losing attractiveness as a global pharmaceutical production hub, despite the diversification to the generic and biologic drug production. Headline Expenditure Projections ? Pharmaceuticals: USD3.02bn in 2013 to USD3.02bn in 2014; +0.2% in local currency terms. Forecast is below the previous quarter's projection due to new historical numbers. ? Healthcare......
  • Cote d’Ivoire Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 59
    BMI View: Despite our more positive outlook for economic and pharmaceutical growth in Cote d'Ivoire over the long term, the country remains one of the least attractive to multinationals looking to launch innovative products in Africa. This is due to risks in its pharmaceutical environment, including poor patent respect, lack of policy enforcement and approvals expediency and a weak business setting. The healthcare market remains underdeveloped, while the burden of communicable diseases is consid......
  • Myanmar Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 57
    BMI View: The considerable increase in government health expenditure in 2012 highlights Myanmar's commitment to improving healthcare. However, there are several barriers to the improvement of medical services, such as limited funding for healthcare, a lack of basic resources and political instability, which could negatively affect Myanmar's economy. Headline Expenditure Projections ? Pharmaceutical imports: MMK324.8bn (US$350mn) in 2013 to MMK387.5bn (US$390mn) in 2014; +19.3% in local currency ......
  • Poland Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 116
    BMI View: Polish pharmacies reported flat year-on-year growth in Q114 sales data. However, BMI expect growth to pick up in the remaining quarters of the year as the country's exports increase and household consumption rises. We highlight consumer healthcare products, especially over-the-counter medicines, as a particularly attractive growth area. Poland's lack of exposure to Russia and the regional tension reinforces our view that the country is one of the most attractive markets in Central and ......
  • Kenya Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 105
    BMI View: The growing Kenyan population will support the growth of the country's pharmaceuticals and healthcare industry. While fertility rates have dropped over the last decade, from 5.0 births per woman in 2003 to 4.4 births per woman in 2013, we note that these figures are well above developed state fertility rates. In 2009, the EU-27 average stood at 1.59 live births per woman. However, we note that the country's young population will act as a limiting factor for pharmaceutical demand, prese......
  • Germany Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 134
    BMI View: Germany's medicines pricing regime will continue to restrict drugmakers' revenue streams. The AMNOG has proved to be tough, with the majority of medicine reimbursement prices lying under the average of or below the lowest of the European reference country basket. Additionally, legislators have voted to continue the 2010 implemented price freeze on reimbursed drugs until the end of 2017. However, the long term and clear nature of the measures implemented by the government is a much more......
  • Canada Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 122
    BMI View: The Canadian pharmaceutical and healthcare market will become increasingly attractive to pharmaceutical companies over the next few years as economic growth in the country gradually accelerates. The hospitable business environment, improving healthcare coverage and broader drug reimbursement lists will continue to provide revenue-generating opportunities for drugmakers. Headline Expenditure Projections ? Pharmaceuticals: CAD25.6bn (USD24.9bn) in 2013 to CAD25.9bn (USD22.5bn) in 2014; +......
  • Turkey Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 125
    BMI View: Data released by the Turkish drugmakers association for 2013 sales corresponds with our own forecasts. We have also modified our pharmaceutical sales forecast for 2014 and beyond to reflect the volatile exchange rate situation. We now see Turkey's lustre as an emerging pharmaceutical market regressing over the medium term. We believe that the business environment will continue to impede the industry and see very little scope for the central government to enact business-friendly reform ......
  • Cameroon Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 58
    BMI View: Mobile health has strong growth potential in Cameroon, given the lack of health infrastructure and medical professionals. The use of mobile health will help to improve accessibility to healthcare, to some extent. However, we maintain that in order for Cameroon to reach its full potential, there needs to be much greater commitment to invest in healthcare services. Headline Expenditure Projections ? Pharmaceuticals: XAF148.82bn (USD300mn) in 2013 to XAF166.95bn (USD320mn) in 2014; +12.2%......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs